|Bid||7,749.00 x 0|
|Ask||7,752.00 x 0|
|Day's range||7,611.00 - 7,779.00|
|52-week range||5,871.00 - 10,120.00|
|Beta (5Y monthly)||0.21|
|PE ratio (TTM)||40.93|
|Earnings date||11 Feb 2021|
|Forward dividend & yield||2.16 (2.82%)|
|Ex-dividend date||13 Aug 2020|
|1y target est||78.83|
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Alexion Pharmaceuticals, Inc. (NasdaqGS: ALXN) to AstraZeneca PLC (NasdaqGS: AZN). Under the terms of the proposed transaction, shareholders of Alexion will receive only $60 in cash and 2.1243 American Depositary Shares (ADSs) of AstraZeneca for each share of Alexion that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Merck (MRK), Glaxo (GSK), AstraZeneca (AZN) and J&J (JNJ) announce FDA approvals.
AstraZeneca's (AZN) Enhertu gets EU approval for metastatic HER2-positive breast cancer patients who have received two or more prior anti-HER2-based regimens.